AU2022409708A1 - Compositions and methods for treating disease - Google Patents

Compositions and methods for treating disease Download PDF

Info

Publication number
AU2022409708A1
AU2022409708A1 AU2022409708A AU2022409708A AU2022409708A1 AU 2022409708 A1 AU2022409708 A1 AU 2022409708A1 AU 2022409708 A AU2022409708 A AU 2022409708A AU 2022409708 A AU2022409708 A AU 2022409708A AU 2022409708 A1 AU2022409708 A1 AU 2022409708A1
Authority
AU
Australia
Prior art keywords
fusion protein
cell
cells
dsg3
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022409708A
Other languages
English (en)
Inventor
Mohammad RASHIDIAN
Soheil TAVAKOLPOUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2022409708A1 publication Critical patent/AU2022409708A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022409708A 2021-12-14 2022-12-14 Compositions and methods for treating disease Pending AU2022409708A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163289595P 2021-12-14 2021-12-14
US63/289,595 2021-12-14
US202263368119P 2022-07-11 2022-07-11
US63/368,119 2022-07-11
PCT/US2022/081559 WO2023114847A2 (en) 2021-12-14 2022-12-14 Compositions and methods for treating disease

Publications (1)

Publication Number Publication Date
AU2022409708A1 true AU2022409708A1 (en) 2024-06-27

Family

ID=85157400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022409708A Pending AU2022409708A1 (en) 2021-12-14 2022-12-14 Compositions and methods for treating disease

Country Status (7)

Country Link
US (1) US20250129136A1 (https=)
EP (1) EP4448561A2 (https=)
JP (1) JP2024546842A (https=)
KR (1) KR20240125951A (https=)
AU (1) AU2022409708A1 (https=)
CA (1) CA3240528A1 (https=)
WO (1) WO2023114847A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183474A1 (en) * 2022-03-23 2023-09-28 Bodhi Bio Llc Antigen-specific therapy for autoimmune diseases
WO2024189620A1 (en) * 2023-03-13 2024-09-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
WO2025253854A1 (ja) * 2024-06-04 2025-12-11 国立大学法人京都大学 Ｂ細胞受容体を発現する細胞の傷害及び／又は除去剤、該剤を含む自己免疫疾患の治療剤及び医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0977800A (ja) * 1995-09-12 1997-03-25 Takeji Nishikawa 融合蛋白質、並びに落葉状天疱瘡の治療薬、治療器具、診断剤及び抗体測定方法
AU2001295503A1 (en) 2000-08-22 2002-03-04 Micromet Ag Composition for the elimination of autoreactive b-cells
EP2050466B1 (en) * 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
EP2123754B1 (en) * 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR

Also Published As

Publication number Publication date
WO2023114847A3 (en) 2023-08-10
JP2024546842A (ja) 2024-12-26
EP4448561A2 (en) 2024-10-23
KR20240125951A (ko) 2024-08-20
CA3240528A1 (en) 2023-06-22
US20250129136A1 (en) 2025-04-24
WO2023114847A2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7587858B2 (ja) ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
JP7465382B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7589269B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
US20240141037A1 (en) Anti-human vista antibodies and use thereof
US20250129136A1 (en) Compositions and methods for treating disease
KR102611270B1 (ko) 면역-pet 영상화를 위한 방사성 표지된 항-pd-l1 항체
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
JP2023509323A (ja) 抗ｃｃｒ８抗体及びその使用
WO2017181109A1 (en) Anti-human vista antibodies and use thereof
EP2820045B1 (en) Methods for the treatment of b cell-mediated inflammatory diseases
CN118922438A (zh) 用于治疗疾病的组合物和方法
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
NZ786412A (en) Anti-human vista antibodies and use thereof